Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT01930552 Completed - Neoplasm Malignant Clinical Trials

A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies

Start date: September 2013
Phase: Phase 1
Study type: Interventional

Primary Objective: To assess the safety and pharmacokinetics preliminarily of the dose of intravenous (IV) aflibercept used in western studies in combination with FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) given intravenously every 2 weeks in Chinese patients with solid tumors. Secondary Objectives: - To make a preliminary assessment of antitumor effects of the combination of FOLFIRI plus aflibercept in patients with measurable disease (RECIST 1.1). - To evaluate the immunogenicity of IV aflibercept.

NCT ID: NCT01928459 Completed - Clinical trials for Advanced Solid Tumors

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Start date: October 2013
Phase: Phase 1
Study type: Interventional

To study the safety and efficacy of the combination of BGJ398 with BYL719 in patients whose tumors express mutations to PIK3CA with or without alterations to FGFR 1-3.

NCT ID: NCT01928394 Active, not recruiting - Clinical trials for Advanced or Metastatic Solid Tumors

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

Start date: October 24, 2013
Phase: Phase 1/Phase 2
Study type: Interventional

To investigate the safety and efficacy of nivolumab as a single agent or in combination with ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), small cell lung cancer (SCLC), bladder cancer (BC), and ovarian cancer (OC). A combination of nivolumab with ipilimumab and cobimetinib is also investigated in PC.

NCT ID: NCT01928290 Completed - Stomach Neoplasms Clinical Trials

Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer

FOLFIRINOX
Start date: November 8, 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well combination chemotherapy works in treating patients with advanced stomach, gastroesophageal, or esophageal cancer. Drugs used in chemotherapy, such as irinotecan hydrochloride, oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

NCT ID: NCT01928030 Terminated - Lymphedema Clinical Trials

Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer

Start date: December 2013
Phase: Phase 1/Phase 2
Study type: Interventional

This pilot phase I/II trial studies the side effects and the best dose of recombinant human hyaluronidase and to see how well it works in treating lymphedema in patients with cancer. Recombinant human hyaluronidase may reduce limb edema size in patients with lymphedema.

NCT ID: NCT01924689 Completed - Clinical trials for Solid Tumor Malignancies

Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

Start date: October 2013
Phase: Phase 1
Study type: Interventional

This protocol will examine the safety of intratumoral administration of Clostridium Novyi-NT spores in patients with treatment-refractory solid tumor malignancies. This investigational study will measure anti-tumor activity of C. novyi-NT administered intratumoral in patients with treatment-refractory solid tumor malignancies.

NCT ID: NCT01923116 Completed - HIV Clinical Trials

Therapeutic HPV-16 Vaccination for the Treatment of Anal Dysplasia

VACCAIN-T
Start date: August 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of the study is to assess, in a phase 1/2 study, the safety and efficacy of this synthetic vaccine SLP-HPV-01® in HIV+ men with CD4 counts > 350 x 10E6/l and HPV16-induced intra-anal high-grade AIN (grade 2-3) that failed on, or recurred after previous treatment.

NCT ID: NCT01922752 Completed - Solid Tumors Clinical Trials

To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors

Start date: July 2013
Phase: Phase 1
Study type: Interventional

The primary objective is to determine the maximum tolerated dose (MTD), safety, and tolerability of oral CEP-37440 administered daily to patients with advanced or metastatic solid tumors.

NCT ID: NCT01921140 Completed - Solid Tumours Clinical Trials

To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours

Start date: September 24, 2013
Phase: Phase 1
Study type: Interventional

This is a 3 part study for patients with solid tumours. The purpose of Part A is to measure the amount of olaparib or its breakdown products in the bloodstream for up to 72 hours after eating and the effect of olaparib on QT interval following a single oral dose of olaparib tablets. Part B will determine the effect of olaparib on the QT interval following multiple oral dosing. Part C will allow patients continued access to olaparib tablets and will provide additional safety data collection.

NCT ID: NCT01918605 Terminated - Prostatic Neoplasms Clinical Trials

Protection of Rectum From High Radiation Doses Using a Spacer

Start date: June 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the usefulness of diluted and non-diluted DuraSeal product as a spacer between prostate and rectum in prostate cancer low-dose brachytherapy.